Boosting mass spectrometry-based analytics for biopharma
- C.J. Gstöttner
- Tuesday 30 November 2021
2311 GJ Leiden
- Prof. M. Wuhrer
Antibody-based drugs are the largest class of biopharmaceuticals produced. They are currently employed to treat diverse diseases such as cancer, cardiovascular or neurologic diseases. Whereas some years ago, efforts were focused on developing classical monoclonal antibodies (mAbs), nowadays there is a trend towards engineered antibodies with enhanced functions, such as bispecific antibodies (BsAbs). These molecules increase in structural complexity and bring new challenges for their analytical characterization. Furthermore, the continuous development of new antibody treatments and molecules also increases the pressure in the analytical labs longing for more automation and high-throughput mass spectrometric analysis. This thesis addresses these aspects and provide solutions for improved and efficient characterization of novel antibody therapeutics focusing on mass spectrometric approaches. These approaches are based on multidimensional liquid chromatography or capillary electrophoresis hyphenated to mass spectrometry or on the application of in-source decay fragmentation. Next to structural characterization, in this thesis MS-based approaches have been developed for their functional characterization permitting to study the relationships between antibody structure and function.
PhD dissertations by Leiden PhD students are available digitally after the defence through the Leiden Repository, that offers free access to these PhD dissertations. Please note that in some cases a dissertation may be under embargo temporarily and access to its full-text version will only be granted later.
Press enquiries (journalists only)
+31 71 527 7211